2023
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
Blauvelt A, Armstrong A, Merola J, Strober B, De Cuyper D, Peterson L, Davies O, Stark J, Lebwohl M. Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders. SKIN The Journal Of Cutaneous Medicine 2023, 7: s300. DOI: 10.25251/skin.7.supp.300.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPHQ-9 scoresPHQ-9Severe plaque psoriasisLonger-term depressionPlaque psoriasisModerate-severe depressionRisk of depressionSuicidal ideationPatient Health Questionnaire (PHQ)-9Moderate to severe plaque psoriasisPHQ-9 dataElevated PHQ-9 scoresGeneral psoriasis populationAnalysis of mental healthDepressionMental healthHigher scoresSuicideLong-term incidence rateAdverse eventsPsoriasis populationScore 0Adjudication committeeWk16
2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2017, 78: 70-80. PMID: 29102053, DOI: 10.1016/j.jaad.2017.08.051.Peer-Reviewed Original ResearchConceptsImpact of treatmentPsoriasis Longitudinal AssessmentConventional therapyAdverse eventsDepressive symptomsIncidence rateLongitudinal assessmentConventional systemic therapiesSevere psoriasisBiologic therapySystemic therapyLower incidenceStudy populationPatientsTherapySymptomsPsoriasisRegistryBiologicsPhototherapyDepressionIncidenceMultivariate modelingRiskTreatment